UPDATE: Leerink Says Tekmira Is 'Uniquely Positioned'

Tekmira Pharmaceuticals TKMR shares are trading seven percent higher Monday after Leerink revealed a $25 price target and Outperform rating.

The company has significant opportunity beyond Ebola with its RNAi product and pipeline, according to the research report. These factors make Tekmira “uniquely positioned.”

TKM-HBV, Tekmira’s hepatitis B drug has the potential to be a major growth catalyst says analyst Michael Schmidt. An investigational new drug application is expected to be filed in the second half of 2015.

Related Link: Deutsche Bank Raises Achillion Price Target 138%

Tekmira shares are up 106 percent over the past month; the company is one of few names mentioned in the recent Ebola outbreak. Shares fell 50 percent from peak to trough last week, but today’s rally is fueling a recovery.

The issue was last trading hands at $19.30, a 6.75 percent gain.